• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含磷脂心磷脂和氟喹诺酮左氧氟沙星的脂质体对广泛耐药结核分枝杆菌的抗菌作用

Antibacterial Effects of Liposomes Containing Phospholipid Cardiolipin and Fluoroquinolone Levofloxacin on Mycobacterium tuberculosis with Extensive Drug Resistance.

作者信息

Gaidukevich S K, Mikulovich Yu L, Smirnova T G, Andreevskaya S N, Sorokoumova G M, Chernousova L N, Selishcheva A A, Shvets V I

机构信息

M. V. Lomonosov Moscow State University of Fine Chemical Technologies, Moscow, Russia.

Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow, Russia.

出版信息

Bull Exp Biol Med. 2016 Mar;160(5):675-8. doi: 10.1007/s10517-016-3247-z. Epub 2016 Mar 29.

DOI:10.1007/s10517-016-3247-z
PMID:27021087
Abstract

The effects of liposomes containing phospholipid cardiolipin without antibiotic and loaded with levofloxacin on the growth of Mycobacterium tuberculosis with extensive drug resistance were studied in vitro. Liposomes consisting of cardiolipin alone in a concentration of 335 μM completely suppressed the growth of M. tuberculosis. In order to reduce the minimum inhibitory concentration of cardiolipin, complex liposome preparation consisting of phosphatidylcholin/cholesterol/cardiolipin and loaded with levofloxacin was prepared. Due to this, the cardiolipin concentration was reduced to 33.5 μM (50 μg/ml) and concentration of levofloxacin - to 2 μg/ml.

摘要

研究了不含抗生素但负载左氧氟沙星的含磷脂心磷脂脂质体对广泛耐药结核分枝杆菌生长的体外影响。浓度为335μM的仅由心磷脂组成的脂质体完全抑制了结核分枝杆菌的生长。为了降低心磷脂的最低抑菌浓度,制备了由磷脂酰胆碱/胆固醇/心磷脂组成并负载左氧氟沙星的复合脂质体制剂。由此,心磷脂浓度降至33.5μM(50μg/ml),左氧氟沙星浓度降至2μg/ml。

相似文献

1
Antibacterial Effects of Liposomes Containing Phospholipid Cardiolipin and Fluoroquinolone Levofloxacin on Mycobacterium tuberculosis with Extensive Drug Resistance.含磷脂心磷脂和氟喹诺酮左氧氟沙星的脂质体对广泛耐药结核分枝杆菌的抗菌作用
Bull Exp Biol Med. 2016 Mar;160(5):675-8. doi: 10.1007/s10517-016-3247-z. Epub 2016 Mar 29.
2
[The effect of liposomes on the growth and sensitivity of Mycobacterium smegmatis to isoniazide].[脂质体对耻垢分枝杆菌生长及对异烟肼敏感性的影响]
Prikl Biokhim Mikrobiol. 2007 Jan-Feb;43(1):47-52.
3
Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.外排泵系统在结核分枝杆菌对氟喹诺酮类和利奈唑胺耐药性中的重要性。
Chemotherapy. 2007;53(6):397-401. doi: 10.1159/000109769. Epub 2007 Oct 12.
4
Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.对具有gyrA基因突变的结核分枝杆菌进行左氧氟沙星最低抑菌浓度的测定。
Int J Tuberc Lung Dis. 2015 Oct;19(10):1227-9. doi: 10.5588/ijtld.14.0277.
5
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.结核分枝杆菌对异烟肼、利福平及左氧氟沙星与其各自结构类似物的交叉耐药性评估。
J Antibiot (Tokyo). 2014 Nov;67(11):749-54. doi: 10.1038/ja.2014.61. Epub 2014 Jun 4.
6
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.氟喹诺酮类和利奈唑胺对结核分枝杆菌对数期和稳定期培养物的作用。
Chemotherapy. 2004 Nov;50(5):211-3. doi: 10.1159/000081707. Epub 2004 Oct 26.
7
[Levofloxacin susceptibility of Mycobacterium tuberculosis].[结核分枝杆菌对左氧氟沙星的敏感性]
Antibiot Khimioter. 2005;50(12):16-8.
8
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.含 3-烷氧基亚氨基-4-(环丙基亚氨基甲酰基)吡咯烷部分的氟喹诺酮衍生物的合成、抗分枝杆菌和抗菌活性。
Eur J Med Chem. 2015 Nov 2;104:73-85. doi: 10.1016/j.ejmech.2015.09.030. Epub 2015 Sep 30.
9
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.台湾某医学中心1995 - 2003年结核分枝杆菌复合群对氟喹诺酮类药物的耐药趋势
J Antimicrob Chemother. 2005 Dec;56(6):1058-62. doi: 10.1093/jac/dki353. Epub 2005 Oct 4.
10
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.三种抗菌药物联合抗结核分枝杆菌时的体外协同作用测定
Int J Antimicrob Agents. 2005 Oct;26(4):292-7. doi: 10.1016/j.ijantimicag.2005.05.005.

引用本文的文献

1
Advanced drug delivery and therapeutic strategies for tuberculosis treatment.用于结核病治疗的先进药物输送和治疗策略。
J Nanobiotechnology. 2023 Nov 9;21(1):414. doi: 10.1186/s12951-023-02156-y.
2
A novel microbe-drug association prediction model based on stacked autoencoder with multi-head attention mechanism.基于堆叠自编码器和多头注意力机制的新型微生物药物关联预测模型。
Sci Rep. 2023 May 6;13(1):7396. doi: 10.1038/s41598-023-34438-8.
3
Nanobiosystems for Antimicrobial Drug-Resistant Infections.用于抗微生物药物耐药性感染的纳米生物系统。
Nanomaterials (Basel). 2021 Apr 22;11(5):1075. doi: 10.3390/nano11051075.
4
Advances in nanomedicine for the treatment of ankylosing spondylitis.纳米医学在治疗强直性脊柱炎方面的进展。
Int J Nanomedicine. 2019 Oct 29;14:8521-8542. doi: 10.2147/IJN.S216199. eCollection 2019.
5
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.结核病中的纳米技术:现状与未来挑战。
Pharm Res. 2018 Sep 20;35(11):213. doi: 10.1007/s11095-018-2497-z.
6
Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.评估小沟结合物(MGBs)作为新型抗分枝杆菌药物,以及使用非离子表面活性剂囊泡作为递送系统来提高其疗效的影响。
J Antimicrob Chemother. 2017 Dec 1;72(12):3334-3341. doi: 10.1093/jac/dkx326.